Single Dose Study To Study The Absorption, Metabolism And Excretion Of PF-04991532

Completed · Phase 1

Conditions studied: Healthy

In brief

The purpose of this study is to evaluate the excretion balance, metabolic profile and the routes of excretion of \[14C\]PF-04991532 in healthy adult male subjects.

Key facts

Study ID

NCT01469481

Run by

Pfizer

People needed

6

Starts

2011-11-01

Expected to finish

2011-11-01

Last updated by the study team

2012-01-31

Who can join

Age: 18 and older, up to 55. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Healthy male subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg(110 lbs).
• An informed consent document signed and dated by the subject.

You may not qualify if…

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) or clinical findings at Screening.
• History of irregular bowel movements (eg, irritable bowel syndrome or frequent episodes of diarrhea or constipation).
• Any condition possibly affecting drug absorption (eg, appendectomy, gastrectomy).

Where it is running

• Pfizer Investigational Site — Tacoma, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.